77
Participants
Start Date
November 30, 2013
Primary Completion Date
February 29, 2016
Study Completion Date
May 31, 2016
Carfilzomib, proteasome inhibitor; intravenous
multiple dose, single schedule
Filanesib, KSP(Eg5) inhibitor; intravenous
multiple dose, single schedule
Dexamethasone, steroid; oral or intravenous
as indicated, per the carfilzomib prescribing information
Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
standard of care
Memorial Sloan Kettering, New York
Virginia Cancer Specialists, Fairfax
WVU - Mary Babb Randolph Cancer Center, Morgantown
Levine Cancer Institute, Charlotte
Florida Cancer Specialists, Fort Myers
Sarah Cannon Research Institute, Nashville
Forrest General Cancer Center, Hattiesburg
Ohio State University, Columbus
Cleveland Clinic, Cleveland
Oncology Hematology Care - Blue Ash, Cincinnati
Karmanos Cancer Institute, Detroit
Medical College of Wisconsin Cancer Center, Milwaukee
Prairie Lakes Health Care System, Watertown
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Nebraska Cancer Specialists, Omaha
Crescent City Research Consortium, Marrero
Genesis Cancer Center, Hot Springs
Simmons Cancer Center - UT Southwestern Medical Center, Dallas
UCLA, Los Angeles
St. Joseph Heritage Healthcare, Santa Rosa
Knight Cancer Institute at Oregon Health & Science University, Portland
Massachusetts General Hospital, Boston
Lead Sponsor
Pfizer
INDUSTRY